Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 1:34 PM ET


Company Overview of Samsung Biologics Co., Ltd.

Company Overview

Samsung Biologics Co., Ltd. develops biological products through genetic engineering, cell culture technology, purification, and fill and finish technology. The company offers process development services, including cell line development programs, and upstream and downstream process development services, as well as develops, qualifies, and validates product-specific analytical methods. It also provides contract management services that comprise cGMP manufacturing programs for cell line development, process and analytical development, clinical phase I/II/III manufacturing, full-scale commercial manufacturing, and aseptic fill and finish operations. The company has a strategic alliance with Me...

125, Cheomdan-daero


Incheon,  406-840

South Korea

Key Executives for Samsung Biologics Co., Ltd.

Chief Executive Officer, President and Director
Vice President of Corporate Business Operation Team
Chief Information Officer and Vice President
Executive Vice President and Director
Senior Vice President
Compensation as of Fiscal Year 2015.

Samsung Biologics Co., Ltd. Key Developments

Samsung Biologics Co., Ltd. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM

Samsung Biologics Co., Ltd. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Tae-Han Kim, Chief Executive Officer, President and Director.

Samsung Reportedly Considers Biotech Partners To Unload Shares

Samsung Electronics Co. Ltd. (KOSE:A005930) reportedly seeks sale of stakes in Samsung C&T Corp. (KOSE:A028260). Samsung Electronics is considering selling off Samsung C&T shares owned by Samsung SDI Co. Ltd. (KOSE:A006400) to its bio technology partners, possibly global pharmaceutical companies, The Herald Business reported on December 28, 2015. Citing the nation's antitrust rules that prohibit conglomerates from creating a new circular ownership through equity investments, the watchdog ordered Samsung SDI to unload 5 million or 2.6% shares in Samsung C&T by the March 1, 2016, deadline. Samsung Electronics said it would comply with the decision but could ask for a grace period to minimize the market impact. The report said the shares could be purchased by partners of Samsung C&T's pharmaceutical unit Samsung Biologics Co., Ltd. as part of Samsung Electronics's recent push into bio technology as its next growth engine. "Samsung Electronics could seek to unload not just the 2.6% shares but also all of Samsung C&T shares owned by other Samsung Electronics affiliates," a source was quoted as saying. "Several bidders have already expressed their intention to purchase,” a source said.

Samsung BioLogics to Construct Biopharmaceutical Manufacturing Plant

Samsung BioLogics celebrated the groundbreaking of its third plant in Incheon Free Economic Zone, Songdo, Korea. With a total investment of KRW 850 billion, the third plant will be a facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation. Once it begins operation, Samsung BioLogics expects to become the biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters. Once the third plant is in full operation, Samsung BioLogics expects it will be able to reach KRW 2 trillion in annual sales and KRW 1 trillion in operating profit. In the longer term, the company plans to continuously expand its CMO business with further investments planned for 4th and 5th plants. Samsung BioLogics' first plant has recently received official approval for production from the U.S. Food and Drug Administration, and its second plant is scheduled to begin operation in early 2016.

Similar Private Companies By Industry

Company Name Region
Hucord Co.,Ltd. Asia
ForHuman Tech Co., Ltd. Asia
BIONGENE Co., Ltd. Asia
Hurimbiocell Inc. Asia
Pion-Tech Co., Ltd. Asia

Recent Private Companies Transactions

Private Placement
July 3, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Samsung Biologics Co., Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at